secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0001370053-23-000052
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Chairman James Topper resigns; John Orwin named Chairman
-------------------------------------------------------------------

- James Topper resigned as Class II director and Chairman effective Sept 15, 2023; no disagreement with company.
- Topper will serve as advisor to the Board through Q1 2024 under an Advisory Agreement.
- John Orwin appointed Class II director and Chairman on Sept 15, 2023.
- Orwin received initial equity grants: option for 3,311 shares (vesting monthly to Jan 2024) and 2,035 RSUs (vest at 2024 annual meeting).
- Orwin also granted option for 10,600 shares (3-year monthly vest) and 3,900 RSUs (3-year annual vest).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000052/0001370053-23-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000052/anab-20230914.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer